Astavrou, I would have defended you in your other previous posts as someone who accidently overlooked the cash raise. With this thread though, you are actively making unsubstantiated and misleading claims in your comparison to AJM and PLS.
To clear the air:
Regarding your point 1
- AJM reported an average cash cost of US$392/wmt - see annual report
- PLS expects cash costs of US$320-350/dmt when they return to normal operations (but recorded US$530/dmt in Q3, which is one of the reasons they are struggling) - see their recent quarterly
- MLL PFS2 operating cash cost is expected to be around US$281/t. This is before further potential cost reductions to power and transport - see MLL Announcement on 7 October 19
Regarding your point 2
- PLS reported spod sales prices of US$580-640 - annual report
- Platts (S&P Global) reported US$540/dmt
- Many Chinese battery manufacturers are heavily investing in Europe - much closer than China and most planned around the time we expect to be commissioning. A quick google search will show you this. Here's a decent read https://www.google.com/amp/s/www.greentechmedia.com/amp/article/europe-set-to-race-past-us-in-battery-manufacturing
To help with some of your other points:
- CRIMM (Minmetals subsidiary) are testing our ore
- DFS is expected Q1 2020
Misinformation aside, yes MLL could be seen as a risky play, in a land-locked country, and we could be a waiting few years. But majority of the holders here know this. Majority of holders have probably been here for that long already.
Anyways, thanks for stopping by and making me do my own research again. I'm here to stay for a while longer.
Full disclosure - I hold PLS as well.
DYOR, not investment advice etc.
- Forums
- ASX - By Stock
- FFX
- MLL has a questionable project under the currently depressed lithium market
MLL has a questionable project under the currently depressed lithium market, page-8
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add FFX (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online